Characteristics of study cohort
| Test cohort | Validation cohort | p Value | |
|---|---|---|---|
| No. of subjects | 57 | 10 | |
| Age in years, mean±SD | 31±10 | 34±17 | 0.701 |
| Men, n (%) | 21 (37) | 4 (40) | 1.000 |
| Genotype, n (%) ΔF508/ΔF508 | 31 (54) | 4 (40) | 0.501 |
| FEV1 % predicted, mean±SD | |||
| Pre | 43±16 | 62±22 | 0.021 |
| Post | 53±18 | 74±20 | 0.009 |
| Difference (Post − Pre) | 10±8 | 11±7 | 0.612 |
| Exacerbation severity (Rosenfeld score), mean±SD | 5.2±1.6 | 5.9±1.3 | 0.125 |
| Sputum culture, n (%) | |||
| Pseudomonas aeruginosa | 44 (77) | 8 (80) | 1.000 |
| Staphylococcus aureus (methicillin sensitive) | 19 (33) | 2 (20) | 0.487 |
| Staphylococcus aureus (methicillin resistant) | 12 (21) | 3 (30) | 0.681 |
| Other (B cepacia, A xylosoxidans, A fumigatus) | 18 (32) | 1 (10) | 0.260 |
| Systemic antibiotic therapy, n (%) | |||
| APAG+4th generation cephalosporin and/or carbapenem and/or monobactam | 50 (88) | 7 (70) | 0.163 |
| Other drugs for P aeruginosa, other Gram-negative rods or S aureus* | 21 (37) | 5 (50) | 0.493 |
| Systemic steroid use, n (%) | 22 (39) | 3 (30) | 0.732 |
| Return to >90% peak FEV, from previous year, post-therapy†, n (%) | 43 (84) | 8 (80) | 0.663 |
| CFRD, n (%) | 23 (40) | 3 (30) | 0.729 |
*Other therapy includes vancomycin, nafcilin, cefazolin, levofloxacin and carbapenem/monobactam combinations.
†From 51 subjects for whom FEV in previous year was available.
B. cepacia, Burkholderia cepacia; A. xylosoxidans, Alcaligenes xylosoxidans; A. fumigatus, Aspergillus fumigatus; APAG, anti-pseudomonal aminoglycoside tobramycin; CFRD, CF-related diabetes mellitus as diagnosed by CF Foundation guidelines; FEV1, forced expiratory volume in 1 s.